METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES

• US 20110070584A1
• Filed: 07/01/2010
• Published: 03/24/2011
• Est. Priority Date: 10/22/2001
• Status: Abandoned Application

• Current Assignee: XDx Incorporated
• Original Assignee: XDx Incorporated
• Inventors: Woodward, Robert, Ly, Ngoc, Fry, Kirk, WOHLGEMUTH, Jay
• Application Number:
  US12/829,172
• Publication Number:
  US 20110070584A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Methods of diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described.

Claims

1. A method of diagnosing or monitoring an autoimmune or chronic inflammatory disease in a patient, comprising detecting the expression level of a gene in said patient to diagnose or monitor said autoimmune or chronic inflammatory disease in said patient wherein said gene is a member of the interferon-induced gene family.

2. The method of claim 1, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:

503, SEQ ID NO;

504, SEQ ID NO;

505, SEQ ID NO;

506, SEQ ID NO;

507, SEQ ID NO;

508, SEQ ID NO;

509, SEQ ID NO;

510, SEQ ID NO;

515, and SEQ ID NO;

516.

3. The method of claim 1, wherein said autoimmune or chronic inflammatory disease is selected from the group consisting of:

Rheumatoid Arthritis, Cholecystitis, Systemic Lupus Erythematosis, Sjogrens Disease, CREST syndrome, Scleroderma, Ankylosing Spondylitis, Crohn'"'"'s, Ulcerative Colitis, Primary Sclerosing Cholangitis, Appendicitis, Diverticulitis, Primary Biliary Sclerosis, Wegener'"'"'s Granulomatosis, Polyarteritis nodosa, Whipple'"'"'s Disease, Psoriasis, Microscopic Polyanngiitis, Takayasu'"'"'s Disease, Kawasaki'"'"'s Disease, Autoimmune hepatitis, Asthma, Churg-Strauss Disease, Beurger'"'"'s Disease, Raynaud'"'"'s Disease, and Cholecystitis.

4. The method of claim 1 wherein said disease is Systemic Lupus Erythematosis.

5. The method of claim 1 wherein said disease is Rheumatoid Arthritis.

6. The method of claim 1 wherein said expression level is detected by measuring the RNA level expressed by said gene.

7. The method of claim 6, further including isolating RNA from said patient prior to detecting said RNA level expressed by said gene.

8. The method of claim 7 wherein said RNA level is detected by PCR.

9. The method of claim 7 wherein said RNA level is detected by hybridization.

10. The method of claim 7 wherein said RNA level is detected by hybridization to an oligonucleotide.

11. The method of claim 10 wherein said oligonucleotide comprises DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.

12. The method of claim 1, wherein said expression level detected is expression level in the patient'"'"'s bodily fluid.

13. The method of claim 12, wherein said bodily fluid is peripheral blood.